• M0064

    Brief office visit for the sole purpose of monitoring or changing drug prescriptions used in the treatment of mental psychoneurotic and personality disorders
  • M0075

    Cellular therapy
  • M0076

    Prolotherapy
  • M0100

    Intragastric hypothermia using gastric freezing
  • M0201

    Covid-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only covid-19 vaccine administration is performed at the patient's home   New
  • M0239

    Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring   Discontinued
  • M0243

    Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring
  • M0244

    Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the covid 19 public health emergency   New
  • M0245

    Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring
  • M0246

    Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the covid 19 public health emergency   New


  • Continued
  • M0247

    Intravenous infusion, sotrovimab, includes infusion and post administration monitoring   New
  • M0248

    Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency   New
  • M0300

    Iv chelation therapy (chemical endarterectomy)
  • M0301

    Fabric wrapping of abdominal aneurysm
  • M1000

    Pain screened as moderate to severe
  • M1001

    Plan of care to address moderate to severe pain documented on or before the date of the second visit with a clinician
  • M1002

    Plan of care for moderate to severe pain not documented on or before the date of the second visit with a clinician, reason not given
  • M1003

    Tb screening performed and results interpreted within twelve months prior to initiation of first-time biologic disease modifying anti-rheumatic drug therapy
  • M1004

    Documentation of medical reason for not screening for tb or interpreting results (i.e., patient positive for tb and documentation of past treatment; patient who has recently completed a course of anti-tb therapy)
  • M1005

    Tb screening not performed or results not interpreted, reason not given
  • M1006

    Disease activity not assessed, reason not given
  • M1007

    >=50% of total number of a patient's outpatient ra encounters assessed
  • M1008

    <50% of total number of a patient's outpatient ra encounters assessed
  • M1009

    Discharge/discontinuation of the episode of care documented in the medical record
  • M1010

    Discharge/discontinuation of the episode of care documented in the medical record
  • M1011

    Discharge/discontinuation of the episode of care documented in the medical record
  • M1012

    Discharge/discontinuation of the episode of care documented in the medical record
  • M1013

    Discharge/discontinuation of the episode of care documented in the medical record
  • M1014

    Discharge/discontinuation of the episode of care documented in the medical record
  • M1015

    Discharge/discontinuation of the episode of care documented in the medical record


  • Continued
  • M1016

    Female patients unable to bear children
  • M1017

    Patient admitted to palliative care services
  • M1018

    Patients with an active diagnosis or history of cancer (except basal cell and squamous cell skin carcinoma), patients who are heavy tobacco smokers, lung cancer screening patients
  • M1019

    Adolescent patients 12 to 17 years of age with major depression or dysthymia who reached remission at twelve months as demonstrated by a twelve month (+/-60 days) phq-9 or phq-9m score of less than 5
  • M1020

    Adolescent patients 12 to 17 years of age with major depression or dysthymia who did not reach remission at twelve months as demonstrated by a twelve month (+/-60 days) phq-9 or phq-9m score of less than 5. either phq-9 or phq-9m score was not assessed or is greater than or equal to 5
  • M1021

    Patient had only urgent care visits during the performance period
  • M1022

    Patients who were in hospice at any time during the performance period
  • M1023

    Adolescent patients 12 to 17 years of age with major depression or dysthymia who reached remission at six months as demonstrated by a six month (+/-60 days) phq-9 or phq-9m score of less than five
  • M1024

    Adolescent patients 12 to 17 years of age with major depression or dysthymia who did not reach remission at six months as demonstrated by a six month (+/-60 days) phq-9 or phq-9m score of less than five. either phq-9 or phq-9m score was not assessed or is greater than or equal to five
  • M1025

    Patients who were in hospice at any time during the performance period
  • M1026

    Patients who were in hospice at any time during the performance period
  • M1027

    Imaging of the head (ct or mri) was obtained
  • M1028

    Documentation of patients with primary headache diagnosis and imaging other than ct or mri obtained
  • M1029

    Imaging of the head (ct or mri) was not obtained, reason not given
  • M1030

    Patients with clinical indications for imaging of the head
  • M1031

    Patients with no clinical indications for imaging of the head
  • M1032

    Adults currently taking pharmacotherapy for oud
  • M1033

    Pharmacotherapy for oud initiated after june 30th of performance period
  • M1034

    Adults who have at least 180 days of continuous pharmacotherapy with a medication prescribed for oud without a gap of more than seven days
  • M1035

    Adults who are deliberately phased out of medication assisted treatment (mat) prior to 180 days of continuous treatment